Growth Metrics

Bio-Rad Laboratories (BIO) Debt to Equity (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Debt to Equity for 17 consecutive years, with $0.16 as the latest value for Q4 2025.

  • Quarterly Debt to Equity fell 11.77% to $0.16 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.16 through Dec 2025, down 11.77% year-over-year, with the annual reading at $0.16 for FY2025, 11.77% down from the prior year.
  • Debt to Equity for Q4 2025 was $0.16 at Bio-Rad Laboratories, down from $0.18 in the prior quarter.
  • The five-year high for Debt to Equity was $0.18 in Q4 2024, with the low at $0.0 in Q3 2021.
  • Average Debt to Equity over 5 years is $0.12, with a median of $0.14 recorded in 2022.
  • The sharpest move saw Debt to Equity tumbled 49.95% in 2021, then soared 20241.86% in 2022.
  • Over 5 years, Debt to Equity stood at $0.0 in 2021, then skyrocketed by 16113.57% to $0.12 in 2022, then grew by 10.13% to $0.14 in 2023, then surged by 33.21% to $0.18 in 2024, then fell by 11.77% to $0.16 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.16, $0.18, and $0.17 for Q4 2025, Q3 2025, and Q2 2025 respectively.